Evidence map›Paper›PMID 29369793›Full record

ArticleNeurobiology of disease2018

Alpha galactosidase A activity in Parkinson's disease.

R N Alcalay, P Wolf, O A Levy, U J Kang, C Waters, S Fahn, B Ford, S H Kuo, N Vanegas, H Shah and 11 more

Open access · greenAbstract read
In one paragraph

Article in Neurobiology of disease, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
46citing papers in PubMed, 3 pooled it
4.6field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

46 citing papers in PubMed, 3 syntheses or guidelines pooled it, 81 citations in OpenAlex.

  1. Association of Rare Variants in ARSA with Parkinson's Disease.Movement disorders : official journal of the Movement Disorder Society · 2023
    Pooled it
  2. Pooled it
  3. Emerging links between pediatric lysosomal storage diseases and adult parkinsonism.Movement disorders : official journal of the Movement Disorder Society · 2019
    Pooled it
  4. Article
  5. Article
  6. Article
  7. Article
  8. The role of sphingolipids in heart failure.European heart journal open · 2025
    Review
  9. Review
  10. Article
  11. Canonical and noncanonical autophagy: involvement in Parkinson's disease.Frontiers in cell and developmental biology · 2025
    Review
  12. Article
  13. Review
  14. Review
  15. Article
  16. Article
  17. Article
  18. Association of rare variants inmedRxiv : the preprint server for health sciences · 2023
    Article
  19. Review
  20. Biochemical Characteristics of iPSC-Derived Dopaminergic Neurons from N370SInternational journal of molecular sciences · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors at 5 institutions in 2 countries.

R N AlcalayDepartment of Neurology, College of Physicians and Surgeons, Columbia University Medical Center, New York, NY, USA; Taub Institute for Research on Alzheimer's Disease and the Aging Brain, College of Physicians and Surgeons, Columbia University Medical Center, New York, NY, USA. Electronic address: rna2104@columbia.edu.
P WolfTranslational Sciences, Sanofi R&D, Framingham, MA, USA.
O A LevyDepartment of Neurology, College of Physicians and Surgeons, Columbia University Medical Center, New York, NY, USA; Taub Institute for Research on Alzheimer's Disease and the Aging Brain, College of Physicians and Surgeons, Columbia University Medical Center, New York, NY, USA.
U J KangDepartment of Neurology, College of Physicians and Surgeons, Columbia University Medical Center, New York, NY, USA.
C WatersDepartment of Neurology, College of Physicians and Surgeons, Columbia University Medical Center, New York, NY, USA.
S FahnDepartment of Neurology, College of Physicians and Surgeons, Columbia University Medical Center, New York, NY, USA.
B FordDepartment of Neurology, College of Physicians and Surgeons, Columbia University Medical Center, New York, NY, USA.
S H KuoDepartment of Neurology, College of Physicians and Surgeons, Columbia University Medical Center, New York, NY, USA.
N VanegasDepartment of Neurology, College of Physicians and Surgeons, Columbia University Medical Center, New York, NY, USA.
H ShahDepartment of Neurology, College of Physicians and Surgeons, Columbia University Medical Center, New York, NY, USA.
C LiongDepartment of Neurology, College of Physicians and Surgeons, Columbia University Medical Center, New York, NY, USA.
S NarayanDepartment of Neurology, College of Physicians and Surgeons, Columbia University Medical Center, New York, NY, USA.
M W PauciuloDivision of Human Genetics, Cincinnati Children's Hospital Medical Center and the Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, OH, USA.
W C NicholsDivision of Human Genetics, Cincinnati Children's Hospital Medical Center and the Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, OH, USA.
Z Gan-OrMontréal Neurological Institute and Hospital, McGill University, Montreal, QC, Canada; Department of Neurology & Neurosurgery, McGill University, Montreal, QC, Canada; Department of Human Genetics, McGill University, Montreal, QC, Canada.
G A RouleauMontréal Neurological Institute and Hospital, McGill University, Montreal, QC, Canada; Department of Neurology & Neurosurgery, McGill University, Montreal, QC, Canada; Department of Human Genetics, McGill University, Montreal, QC, Canada.
W K ChungDepartment of Pediatrics and Medicine, College of Physicians and Surgeons, Columbia University Medical Center, New York, NY, USA.
P OlivaTranslational Sciences, Sanofi R&D, Framingham, MA, USA.
J KeutzerTranslational Sciences, Sanofi R&D, Framingham, MA, USA.
K MarderDepartment of Neurology, College of Physicians and Surgeons, Columbia University Medical Center, New York, NY, USA; Taub Institute for Research on Alzheimer's Disease and the Aging Brain, College of Physicians and Surgeons, Columbia University Medical Center, New York, NY, USA; Gertrude H. Sergievsky Center, College of Physicians and Surgeons, Columbia University, New York, NY, USA.
X K ZhangTranslational Sciences, Sanofi R&D, Framingham, MA, USA.
Columbia University Irving Medical Center · USColumbia University · USMcGill University · CACincinnati Children's Hospital Medical Center · USUniversity of Cincinnati · US

Funding

CTSA INFRASTRUCTURE FOR PEDIATRIC RESEARCHUL1RR024156 · NCRR · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI GINSBERG, HENRY N · 2006 to 2011
$53.0M
Clinical and Translational Science AwardUL1TR000040 · NCATS · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI GINSBERG, HENRY N · 2012 to 2015
$26.2M
ENVIRONMENTAL EPIDEMIOLOGY OF ESSENTIAL TREMORR01NS039422 · NINDS · YALE UNIVERSITY · PI LOUIS, ELAN D · 2000 to 2013
$7.7M
Coenzyme Q10 in Huntingtons DiseaseU01NS052592 · NINDS · MASSACHUSETTS GENERAL HOSPITAL · PI CUDKOWICZ, MERIT E · 2008 to 2013
$7.3M
GENETIC EPIDEMIOLOGY OF PARKINSONS DISEASER01NS036630 · NINDS · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI MARDER, KAREN S · 1998 to 2008
$6.8M
The striatal cholinergic interneurons in Parkinson's disease and treatmentR01NS101982 · NINDS · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI KANG, UN JUNG · 2017 to 2020
$1.8M
The role of glucocerebrosidase in Parkinson's diseaseK02NS080915 · NINDS · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI ALCALAY, ROY · 2012 to 2016
$905k
Genetic Epidemiology of Parkinson's DiseaseR56NS036630 · NINDS · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI MARDER, KAREN S · 2010 to 2010
$500k
Plasticity of bridge collaterals in Parkinonian state and treatmentR03NS096494 · NINDS · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI KANG, UN JUNG · 2016 to 2017
$160k
NCATS NIH HHS UL1 TR000040NCRR NIH HHS UL1 RR024156NINDS NIH HHS K02 NS080915NINDS NIH HHS R01 NS036630NINDS NIH HHS R01 NS039422NINDS NIH HHS R01 NS101982NINDS NIH HHS R03 NS096494NINDS NIH HHS R56 NS036630NINDS NIH HHS U01 NS052592
6 · The paper itself

Abstract

Glucocerebrosidase (GCase, deficient in Gaucher disease) enzymatic activity measured in dried blood spots of Parkinson's Disease (PD) cases is within healthy range but reduced compared to controls. It is not known whether activities of additional lysosomal enzymes are reduced in dried blood spots in PD. To test whether reduction in lysosomal enzymatic activity in PD is specific to GCase, we measured GCase, acid sphingomyelinase (deficient in Niemann-Pick disease types A and B), alpha galactosidase A (deficient in Fabry), acid alpha-glucosidase (deficient in Pompe) and galactosylceramidase (deficient in Krabbe) enzymatic activities in dried blood spots of PD patients (n = 648) and controls (n = 317) recruited from Columbia University. Full sequencing of glucocerebrosidase (GBA) and the LRRK2 G2019S mutation was performed. Enzymatic activities were compared between PD cases and controls using t-test and regression models adjusted for age, gender, and GBA and LRRK2 G2019S mutation status. Alpha galactosidase A activity was lower in PD cases compared to controls both when only non-carriers were included (excluding all GBA and LRRK2 G2019S carriers and PD cases with age-at-onset below 40) [2.85 μmol/l/h versus 3.12 μmol/l/h, p = 0.018; after controlling for batch effect, p = 0.006 (468 PD cases and 296 controls)], and when including the entire cohort (2.89 μmol/l/h versus 3.10 μmol/l/h, p = 0.040; after controlling for batch effect, p = 0.011). Because the alpha galactosidase A gene is X-linked, we stratified the analyses by sex. Among women who were non-carriers of GBA and LRRK2 G2019S mutations (PD, n = 155; control, n = 194), alpha galactosidase A activity was lower in PD compared to controls (2.77 μmol/l/h versus 3.10 μmol/l/h, p = 0.044; after controlling for a batch effect, p = 0.001). The enzymatic activity of acid sphingomyelinase, acid alpha-glucosidase and galactosylceramidase was not significantly different between PD and controls. In non-carriers, most lysosomal enzyme activities were correlated, with the strongest association in GCase, acid alpha-glucosidase, and alpha galactosidase A (Pearson correlation coefficient between 0.382 and 0.532). In a regression model with all five enzymes among non-carriers (adjusted for sex and age), higher alpha galactosidase A activity was associated with lower odds of PD status (OR = 0.54; 95% CI:0.31-0.95; p = 0.032). When LRRK2 G2019S PD carriers (n = 37) were compared to non-carriers with PD, carriers had higher GCase, acid sphingomyelinase and alpha galactosidase A activity. We conclude that alpha galactosidase A may have a potential independent role in PD, in addition to GCase.

Indexed as

Agedalpha-GalactosidaseCohort StudiesEnzyme ActivationFemaleHumansLeucine-Rich Repeat Serine-Threonine Protein Kinase-2MaleMiddle AgedParkinson Diseasealpha-GalactosidaseLeucine-Rich Repeat Serine-Threonine Protein Kinase-2LRRK2 protein, humanBiomarkersLysosomal storage diseaseMovement disordersNeurodegenerationParkinson's disease

Identifiers

PMID29369793
PMCPMC5811339
OpenAlexW2792102607

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.